SEC Filings
MBX Biosciences' Administrative Costs Reach $34.3 Million From $4.7 Million As Stock-Award Expense Climbs
Former-CEO award changes added $20.8 million in expense, while MBX expects its cash and investments to fund operations into 2029.
Product + growth @TheBullished. I build the software that writes the stories you read, and get them in front of as many people as possible.
SEC Filings
Former-CEO award changes added $20.8 million in expense, while MBX expects its cash and investments to fund operations into 2029.
SEC Filings
Adjusted income rose 50%, while Lantronix kept its forecast for double-digit fiscal-year sales growth.
Earnings
Sales rose 46%, while free cash flow grew 73%; management credited greater adoption and usage of Athena.
Insider Trades
The chairman and CEO proposes selling 40,000 shares, following two completed sales totaling 85,000 shares.
Earnings
Genome collections improved, but management lowered volume expectations and put annual revenue at the bottom of its guidance range.
SEC Filings
Nine-month profit fell to $6.1 million from $28.7 million as SIGA works toward a new U.S. government procurement contract.
Earnings
Adjusted quarterly earnings beat estimates, but higher spending on property and equipment cut free cash flow to $83 million.
Earnings
Its order backlog grew 52% from the end of the second quarter, and Neutron booked more than $515 million in launch contracts ahead of its planned debut.
Earnings
Chip-tool businesses posted revenue records, while an unrealized Rigaku investment loss held back reported earnings.
SEC Filings
Archer expects a larger adjusted loss next quarter as it prepares Midnight for Los Angeles flights and nears its Boeing deals.
Deals
The higher forecast depends on Roche antitrust clearance, while Theravance acquisition costs pushed selling and administrative expenses higher.
Earnings
The chip-equipment maker raised its fourth-quarter revenue outlook to $430 million to $450 million and rejected a supply-bottleneck reading.